Solid Biosciences Inc. — FY2020 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2020. Solid Biosciences is a clinical-stage biotechnology company focused on Duchenne muscular dystrophy (Duchenne). Its lead program, SGT-001, is an investigational gene-transfer therapy; the company had no approved products and generated no product revenue. The filing was signed March 15, 2021, and also describes certain subsequent events.
Financial performance and position
| Metric | FY2020 / Dec. 31, 2020 | FY2019 / Dec. 31, 2019 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $64.9 million | $94.7 million |
| General and administrative expense | $21.6 million | $24.6 million |
| Restructuring expense | $1.9 million | $0 |
| Operating loss | $88.4 million | $119.3 million |
| Net loss | $88.3 million | $117.2 million |
| Net loss per share, basic and diluted | $1.70 | $2.91 |
| Cash used in operating activities | $56.6 million | $92.7 million |
| Cash and cash equivalents | $154.7 million | $76.0 million |
| Total assets | $171.2 million | $103.5 million |
| Total liabilities | $39.1 million | $23.4 million |
| Debt outstanding | None | None |
- Gross margin and operating margin are not meaningful measures for this pre-commercial company, which reported no revenue.
- Current assets were $158.9 million and current liabilities $24.5 million at year-end. The company also reported $8.25 million of operating lease, finance lease and unconditional purchase commitments.
- Accumulated deficit was $404.6 million. The independent auditor included a going-concern explanatory paragraph; management concluded substantial doubt existed about the company’s ability to continue as a going concern within one year after issuance of the statements.
Material changes versus the prior comparable period
- Net loss narrowed by $28.9 million, while operating expenses declined by $30.9 million. R&D fell $29.9 million, primarily reflecting lower manufacturing costs, reduced personnel and facility costs following restructuring, and reduced spending on other programs. G&A declined $3.0 million. Interest income also decreased, to $0.1 million from $1.6 million.
- Operating cash use decreased by $36.1 million. The filing attributes the 2020 cash-flow reconciliation partly to $20.7 million of deferred revenue related to the Ultragenyx agreement; that amount was not recognized as 2020 revenue.
- Financing activities provided $128.7 million in 2020, including approximately $86.2 million net from a December private placement, $23.2 million net from at-the-market stock sales, and approximately $40.0 million from the Ultragenyx stock purchase. These equity financings increased the common shares outstanding and diluted existing holders.
- The company reduced its workforce by approximately 30% in January 2020 and recorded $1.9 million of restructuring charges.
Business developments, outlook and risks
- SGT-001 and FDA status: FDA placed the IGNITE DMD Phase I/II trial on clinical hold in November 2019 after a serious drug-related event involving complement activation, thrombocytopenia, acute kidney injury and cardiopulmonary insufficiency. The FDA lifted the hold in October 2020. The amended protocol limits the next two patients to 18 kg or less and includes prophylactic eculizumab and C1 esterase inhibitor, as well as increased prednisone. These measures are unproven in this disease and do not eliminate the risk of further serious adverse events.
- Manufacturing: The company introduced a second-generation process described as producing drug product with an average of 90% full capsids, versus 50% for the first-generation process. The filing states this reduces total capsid load at a given dose. Manufacturing scale, consistency, regulatory acceptability and supply remain important execution risks; production relies on third-party manufacturing partners.
- Post-period clinical update: The filing reports March 2021 interim data from six IGNITE DMD patients, with three low-dose and three high-dose patients, and an untreated control cohort. Company-reported one-year mean 6-minute walk changes were +37 meters at low dose and +49.7 meters at high dose, versus -8.5 meters in controls. The small, early-stage dataset is preliminary and does not establish efficacy. Complement activation occurred in all six treated patients; two related serious adverse events had resolved. The company also reported that a seventh patient treated under the amended protocol had reduced complement activation without clinical manifestations. These are subsequent-period updates, not FY2020 financial results.
- Ultragenyx collaboration: The October 2020 agreement grants Ultragenyx exclusive worldwide rights for specified AAV8/clade E microdystrophin products, while Solid retains rights to its SGT-001 program and other uses. Ultragenyx may owe up to $255 million in cumulative milestones per product, plus tiered royalties; Solid has options to share development costs and, subject to terms, U.S./EU profits and losses. No collaboration revenue was recognized in 2020; $20.7 million was recorded as deferred revenue. Future milestone and royalty receipts are contingent and uncertain.
- Runway and funding: Management said year-end cash was expected to fund operations into the first quarter of 2022, based on assumptions that may prove incorrect. Additional financing will be needed to continue beyond that point, and there is no assurance it will be available on acceptable terms. The filing does not provide product-sales guidance; management does not expect product revenue for several years, if ever.
- Other risks and contingencies: COVID-19 caused some postponed trial visits and biopsies, although the company said recent visits had not been missed or postponed. Other key risks include clinical and regulatory failure, gene-therapy safety, competition, manufacturing and supply constraints, dependence on licensed intellectual property, future dilution, and reimbursement uncertainty. A prior stockholder class action was voluntarily dismissed without prejudice in June 2019; the filing reports no other material claims as of year-end.
Most important facts for investors to verify
- Cash runway assumptions, forecast cash burn and the timing and terms of any additional financing; the auditor’s going-concern warning is explicit.
- Full clinical-trial data, patient-level outcomes, durability and safety—including complement-related events—and whether the small interim results are confirmed in larger controlled studies.
- FDA requirements for continued IGNITE DMD enrollment, including the amended safety protocol, viral-load limits and any additional manufacturing or clinical conditions.
- Second-generation manufacturing reproducibility, yields, capacity, regulatory comparability and dependence on third-party manufacturers.
- Ultragenyx program progress, Solid’s exercise of development or income-share options, and the conditions and timing attached to any milestones or royalties.
- Share-count changes, remaining financing capacity and potential dilution; common shares issued and outstanding were 84.9 million at year-end and 85.1 million as of February 16, 2021.